PMID- 27225316
OWN - NLM
STAT- MEDLINE
DCOM- 20170614
LR  - 20220318
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 137
IP  - 6
DP  - 2016 Jun
TI  - Prenatal Fish Oil Supplementation and Allergy: 6-Year Follow-up of a Randomized 
      Controlled Trial.
LID - e20154443 [pii]
LID - 10.1542/peds.2015-4443 [doi]
AB  - BACKGROUND AND OBJECTIVE: Evidence from randomized controlled trials in early 
      infancy suggest that prenatal supplementation with Omega-3 (n-3) long-chain 
      polyunsaturated fatty acids (LCPUFA) reduces the incidence of allergic disease 
      characterized by an immunoglobulin E (IgE) response. We aimed to determine 
      whether protective effects were evident in the 6-year-old offspring of women 
      supplemented with n-3 rich fish oil during pregnancy. METHODS: Six-year follow-up 
      of children (n = 706) with a family history of allergic disease from the 
      Docosahexaenoic Acid to Optimize Mother Infant Outcome (DOMInO) trial. Women were 
      randomly allocated to receive n-3 LCPUFA-rich fish oil capsules (800 mg/d 
      docosahexaenoic acid DHA and 100mg/d eicosapentaenoic acid) or vegetable oil 
      capsules (without n-3 LCPUFA). Allergic disease symptoms including eczema, 
      wheeze, rhinitis, and rhino-conjunctivitis, were assessed using the International 
      Study of Asthma and Allergies in Childhood questionnaire and sensitization to 
      allergens was measured by skin prick test. RESULTS: There was no difference in 
      the percentage of children with any IgE-associated allergic disease between the 
      n-3 LCPUFA and control groups (116/367 [31.5%] vs 106/336 [31.5%]; adjusted 
      relative risk, 1.04; 95% confidence interval, 0.82-1.33; P = .73). There was a 
      reduction in the percentage of children sensitized to house dust mite 
      Dermatophagoides farinae (49/367 [13.4%] vs 68/336 [20.3%]; adjusted relative 
      risk, 0.67, 95% confidence interval, 0.44-1.00; P = .0495). CONCLUSIONS: Prenatal 
      n-3 LCPUFA supplementation did not reduce IgE-associated allergic disease at 6 
      years of age. Secondary outcomes were suggestive of a protective effect of the 
      intervention on the incidence of D. farinae sensitization.
CI  - Copyright (c) 2016 by the American Academy of Pediatrics.
FAU - Best, Karen P
AU  - Best KP
AD  - Healthy Mothers, Babies and Children, South Australian Health and Medical 
      Research Institute, Adelaide, South Australia, Australia; Women's & Children's 
      Health Research Institute, Discipline of Paediatrics, School of Medicine, and 
      karen.best@adelaide.edu.au.
FAU - Sullivan, Thomas
AU  - Sullivan T
AD  - School of Population Health, University of Adelaide, Adelaide, South Australia, 
      Australia;
FAU - Palmer, Debra
AU  - Palmer D
AD  - Women's & Children's Health Research Institute, School of Paediatrics and Child 
      Health, University of Western Australia, Subiaco, Western Australia, Australia; 
      and.
FAU - Gold, Michael
AU  - Gold M
AD  - Discipline of Paediatrics, School of Medicine, and.
FAU - Kennedy, Declan John
AU  - Kennedy DJ
AD  - Discipline of Paediatrics, School of Medicine, and Department of Respiratory and 
      Sleep Medicine, Women's & Children's Hospital, North Adelaide, South Australia, 
      Australia.
FAU - Martin, James
AU  - Martin J
AD  - Department of Respiratory and Sleep Medicine, Women's & Children's Hospital, 
      North Adelaide, South Australia, Australia.
FAU - Makrides, Maria
AU  - Makrides M
AD  - Healthy Mothers, Babies and Children, South Australian Health and Medical 
      Research Institute, Adelaide, South Australia, Australia; Women's & Children's 
      Health Research Institute, Discipline of Paediatrics, School of Medicine, and.
LA  - eng
SI  - ANZCTR/ACTRN12615000498594
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Child
MH  - Dermatophagoides farinae/immunology
MH  - *Dietary Supplements
MH  - Docosahexaenoic Acids/*administration & dosage
MH  - Eicosapentaenoic Acid/*administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypersensitivity/*epidemiology/immunology/prevention & control
MH  - Immunoglobulin E/analysis
MH  - Male
MH  - Pregnancy
MH  - Prenatal Care
MH  - *Prenatal Exposure Delayed Effects
EDAT- 2016/05/27 06:00
MHDA- 2017/06/15 06:00
CRDT- 2016/05/27 06:00
PHST- 2016/03/22 00:00 [accepted]
PHST- 2016/05/27 06:00 [entrez]
PHST- 2016/05/27 06:00 [pubmed]
PHST- 2017/06/15 06:00 [medline]
AID - peds.2015-4443 [pii]
AID - 10.1542/peds.2015-4443 [doi]
PST - ppublish
SO  - Pediatrics. 2016 Jun;137(6):e20154443. doi: 10.1542/peds.2015-4443.